The European Medicines Agency has begun reviewing EU marketing authorization applications (MAAs) for a raft of new products, including SK bioscience’s COVID-19 vaccine, Skycovion, and Byondis’s trastuzumab duocarmazine, for treating HER2-positive metastatic breast cancer.
Skycovion (GBP510), which was approved in South Korea in June, is a recombinant protein-based COVID-19 vaccine candidate adjuvanted with








